Citations Appearing in 2009

  1. Abraham, A.K., D.E. Mager, X. Gao, M. Li, D.R. Healy, and T.S. Maurer. Mechanism-based pharmacokinetic/pharmacodynamic model of parathyroid hormone-calcium homeostasis in rats and humans. The Journal of Pharmacology and Experimental Therapeutics 330(1):169-178, 2009.
  2. Abuelkheir, M.M. Effect of pharmacokinetic differences between men and women on pharmacodynamic target attainment of levofloxacin against streptococcus pneumoniae. Saudi Pharmaceutical Journal 17(1):29-39, 2009.
  3. Ambrose, P.G., A.K. Meagher, J.A. Passarell, S.A. Van Wart, B.B. Cirincione, S.M. Bhavnani, and E. Ellis-Grosse. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagnostic Microbiology and Infectious Disease 63(2):155-159, 2009.
  4. Bender, G., J. Gosset, J. Florian, K. Tan, M. Field, S. Marshall, J. DeJongh, R. Bies, and M. Danhof. Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design.Pharmaceutical Research 26(10):2259-2269, 2009.
  5. Beringer, P.M., L. Hidayat, A. Heed, L. Zheng, H. Owens, D. Benitez, and A.P. Rao. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. Journal of Cystic Fibrosis 8(1):19-25, 2009.
  6. Bertera, F.M., C.A. Di Verniero, M.A. Mayer, G.F. Bramuglia, C.A. Taira, and C. Höch. Is urethane–chloralose anaesthesia appropriate for pharmacokinetic–pharmacodynamic assessment? Studies with carvedilol. Journal of Pharmacological and Toxicological Methods 59(1):13-20, 2009.
  7. Bertera, F.M., M.A. Mayer, J.A.W. Opezzo, C.A. Taira, and C. Höcht. Increased sensitivity to diltiazem hypotensive effect in an experimental model of high-renin hypertension. Journal of Pharmacy and Pharmacology 61(1):79-87, 2009.
  8. Britten, C.D., R.S. Finn, L.D. Bosserman, S.G. Wong, M.F. Press, M. Malik, B.L. Lum, and D.J. Slamon. A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach. Clinical Breast Cancer 9(1):16-22, 2009.
  9. Bulitta, J.B., C.B. Landersdorfer, M. Kinzig, U. Holzgrabe, and F. Sorgel. New semiphysiological absorption model to assess the pharmacodynamic prile of cfuroxime aetil using nonparametric and parametric population pharmacokinetics.Antimicrobial Agents and Chemotherapy 53(8):3462-3471, 2009.
  10. Bulitta, J.B., N.S. Ly, J.C. Yang, A. Forrest, W.J. Jusk, and B.T. Tsuji. Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 53(1):46-56, 2009.
  11. Chadwick, E.G., J. Pinto, R. Yogev, C.G. Alvero, M.D. Hughes, P. Palumbo, B. Robbins, R. Hazra, L. Browning, B. E. Heckman, L. Purdue, R. Browning, K. Luzuriaga, J. Rodman, E. Capparelli, and Cli Int Maternal Pediat Adolescent. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age pharmacokinetics and 24-Week safety and efficacy. Pediatric Infectious Disease Journal 28(3):215-219, 2009.
  12. Christiansen, S.R., A. Broniscer, J.C. Panetta, and C.F. Stewart. Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and literature review. Pharmacotherapy 29(7):858-866, 2009.
  13. Colucci, P., J.C. Pottage, H. Robison, J. Turgeon, and M.P. Ducharme. Effect of a single dose of ritonavir on the pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered in healthy volunteers. Antimicrobial Agents and Chemotherapy 53(2):646-650, 2009.
  14. Colucci, P., J.C. Pottage, H. Robison, J. Turgeon, D. Schurmann, I.M. Hoepelman, and M.P. Ducharme. Multiple-dose pharmacokinetic behavior of elvucitabine, a nucleoside reverse transcriptase inhibitor, administered over 21 days with lopinavir-ritonavir in human immunodeficiency virus type 1-infected subjects. Antimicrobial Agents and Chemotherapy 52(3):662-669, 2009.
  15. Cross, S.J., J.H. Rodman, J.C. Lindsey, B.L. Robbins, C.H. Rose, G.J. Yuen, and L.J. D’Angelo. Abacavir and metabolite pharmacokinetics in HIV-1–infected children and adolescents. Journal of Acquired Immune Deficiency Syndromes 51(1):54-59, 2009.
  16. Curras, V., C. Höcht, A. Mangano, V. Niselman, E.M. Hernández, P.C. Guido, D. Mecikovsky, C. Bellusci, R. Bologna, L. Sen, M.C. Rubio, and G.F. Bramuglia. Pharmacokinetic study of the variability of indinavir drug levels when boosted with ritonavir in HIV-infected children. Pharmacology 83(1):59-56, 2009.
  17. Drake, A.S., M.T. Brady, X.H. Wang, S.J.N. Sait, J.C. Earp, S. Ghoshal (Gupta), S. Ferrone, E.S. Wang, and Meir Wetzler. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunology 58(3):415-247, 2009.
  18. Drusano, G.L., W. Liu, C. Fregeau, R. Kulawy, and A. Louie. Differing effect of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance on wild-type Pseudomonas aeruginosa PA01 and its isogenic MexAB efflux pump overexpressed mutant. Antimicrobial Agents and Chemotherapy 53(6):2266-2273, 2009.
  19. Drusano, G.L., W. Liu, D.L. Brown, L.B. Rice, and A. Louie. Impact of short-course quinolone therapy on susceptible and resistant populations of staphylococcus aureus. Journal of Infectious Diseases 199(2):219-226, 2009.
  20. Ezzeldin, H.H., E.P. Acosta, L.K. Mattison, J. Fourie, A. Modak, and R.B. Diasio. 13C-5-FU breath test current status and future directions: a comprehensive review. Journal of Breath Research 3(4):1-12, 2009.
  21. Finkelstein, Y., A.A. Nava-Ocampo, T. Schechter, M.R. Grant, E.S. Pierre, R. Goldman, S. Walker, and G. Koren. Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs. Fundamental and Clinical Pharmacology 23(1):53-57, 2009.
  22. Fouad, E.A., M.S. Ali, H.M.I. Kotb, S. Emara, M.S. Fracs, and A. El Minshawy. Effect of cardiopulmonary bypass on the pharmacokinetics of intravenous paracetamol. Saudi Pharmaceutical Journal 17(2):130-136, 2009.
  23. French, D., W. Yang, C. Cheng, S.C. Raimondi, C.G. Mullighan, J.R. Downing, W.E. Evans, C. Pui, and M.V. Relling. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia. Blood 113(19):4512-4520, 2009.
  24. Fukasawa, A., T. Aoyama, T. Nagashima, N. Fukuda, T. Ueno, H. Sugiyama, H. Nagase, and Y. Matsumoto. Pharmacokinetics of pyrrole-imidazole polyamides after intravenous administration in rat. Biopharmaceutics and Drug Disposition 30(2):81-89, 2009.
  25. Fukudo, M., I. Yano, K. Shinsako, T. Katsura, Y. Takada, S. Uemoto, and K. Inui. Prospective evaluation of the bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. Journal of Clinical Pharmacology 49(7):789-797, 2009.
  26. Gorlick, R., E.A. Kolb, P.J. Houghton, C.L. Morton, D. Phelps, P. Schaiquevich, C. Stewart, S.T. Keir, R. Lock, H. Carol, C.P. Reynolds, J.M. Maris, J. Wu, and M.A. Smith. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. Pediatric Blood and Cancer 53(4):594-598, 2009.
  27. Gumbo, T., C.S. Dona, C. Meek, and R. Leff. Pharmacokinetics-pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrobial Agents and Chemotherapy 53(8):3197-3204, 2009.
  28. Guo, J., R.A. Parise, E. Joseph, M.J. Egorin, J.S. Lazo, E.V. Prochownik, and J.L. Eiseman. Efficacy, pharmacokinetics, tissue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemotherapy and pharmacology 63(4):615-625, 2009.
  29. Harrold, J. M., and R. S. Parker. Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization. Computers and Chemical Engineering 33(12):2042-2054, 2009.
  30. Hubbard, K. E., P. Schaiquevich, F. Bai, C. H. Fraga, L. Miller, J. C. Panetta, and C. F. Stewart. Application of a highly specific and sensitive fluorescent HPLC method for topotecan lactone in whole blood. Biomedical Chromatography 23(7):707-713, 2009.
  31. Jelliffe, R., A. Schumitzky, D. Bayard, R. Leary, A. Botnen, M.V. Guilder, A. Bustad, and M. Neely. Human genetic variation, population pharmacokinetic – dynamic models, bayesian feedback control, and maximally precise individualized drug dosage regimens. Current Pharmacogenomics and Personalized Medicine 7(4):249-262, 2009.
  32. Jin, J.Y. and W.J. Jusko. Pharmacodynamics of glucose regulation by methylprednisolone. I. Adrenalectomized rats. Biopharmaceutics and Drug Disposition 30(1):21-34, 2009.
  33. Jin, J.Y. and W.J. Jusko. Pharmacodynamics of glucose regulation by methylprednisolone. II. Normal rats. Biopharmaceutics and Drug Disposition 30(1):35-48, 2009.
  34. Khinkis, L. A., W. Krzyzanski, W. J. Jusk, and W. R. Greco. D-optimal designs for parameter estimation for indirect pharmacodynamic response models. Journal of Pharmacokinetics and Pharmacodynamics 36(6):523-539, 2009.
  35. Kilburm, L.B., P.L. Bonate, S.M. Blaney, L. McGuffey, J.G. Nuchtern, R. Dauser, P. Thompson, B.W. Gibson, and S.L. Berg. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.Cancer Chemotherapy and Pharmacology 64(2):335-340, 2009.
  36. Kim, T.K., W. Kang, I.K. Chun, S.Y. Oh, Y.H. Lee, and H.S. Gwak. Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systems. European Journal of Pharmaceutical Sciences 38(5):525-531, 2009.
  37. Koch, G., A. Walz, G. Lahu, and J. Schropp. Modeling of tumor growth and anticancer effects of combination therapy. Journal of Pharmacokinetics and Pharmacodynamics 36(2):179-197, 2009.
  38. Landersdorfer, C.B., M. Kinzig, F.F. Hennig, J.B. Bulitta, U. Holzgrabe, G.L. Drusano, F. Sörgel, and J. Gusinde. Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation. Antimicrobial Agents and Chemotherapy 53(5):2074-2081, 2009.
  39. Landersdorfer, C. B., M. Kinzig, J. B. Bulitta, F. F. Hennig, U. Holzgrabe, F. Sörgel, and J. Gusinde. Bone penetration of amoxicillin and clavulanic acid evaluated by population pharmacokinetics and monte carlo simulation. Antimicrobial Agents and Chemotherapy 53(6):2569-2578, 2009.
  40. Lin, H., M. Sun, H.Tang, C. Lin, M.K. Luidens, S.A. Mousa, S. Incerpi, G.L. Drusano, F.B. Davis, and P.J. Davis. L-Thyroxine vs. 3,5,3′-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. American Journal of Physiology- Cell Physiology 296(5):980-991, 2009.
  41. Lodise, T. P., N. Patel, B.M. Lomaestro, K.A. Rodvold, and G.L. Drusano. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clinical Infectious Diseases 49(4):507-514, 2009.
  42. Lonnerholm, G., B.M. Frost, S. Soderhall, and S.S.N. de Graaf. Vincristine Pharmacokinetics in Children With Down Syndrome. Pediatric Blood and Cancer 52(1):123-125, 2009.
  43. Louie, A., C. Fregeau, W. Liu, R. Kulawy, and G.L. Drusano. Pharmacodynamics of levofloxacin in a murine pneumonia model of pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrobial Agents and Chemotherapy 53(8):3325-3330, 2009.
  44. Marquet, P., F. Saint-Marcoux, A. Premaud, F. L. Sauvage, E. Jaqz-Aigrain, C. Knoop, Y. Lebranchu, M. Tiberi, I. Domke, and J. Debord. Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of bayesian estimators in different populations of allograft recipients. Therapeutic Drug Monitoring 31(4):443-450, 2009.
  45. McGregor, L.M., S.L. Spunt, W.L. Furman, C.F. Stewart, P. Schaiquevich, M.D. Krailo, R. Speights, P. Ivy, P.C. Adamso, and S.M. Blaney. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors. Cancer 115(8):1765-1775, 2009.
  46. McSharry, J.J., M.R. Deziel, K. Zager, Q. Weng, and G.L. Drusano. Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system. Antimicrobial Agents and Chemotherapy 53(1):129-135, 2009.
  47. McSharry, J.J., Q. Weng, A. Brown, R. Kulawy, and G.L. Drusano. Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza a virus using an in vitro hollow-fiber infection model system. Antimicrobial Agents and Chemotherapy 53(6):2375-2381, 2009.
  48. Miller, A.A., D.J. Murry, K. Owzar, D.R. Hollis, E.B. Kennedy, G. Abou-Alfa, A. Desai, J. Hwang, M.A. Villalona-Calero, E.C. Dees, L.D. Lewis, M.G. Fakih, M.J. Edelman, F. Millard, R.C. Frank, R.J. Hohl, and M.J. Ratain. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. Journal of Clinical Oncology 27(11):1800-1805, 2009.
  49. Min, Y., F. Qiang, L. Peng, and Z. Zhu. High dose methotrexate population pharmacokinetics and bayesian estimation in patients with lymphoid malignancy. Biopharmaceutics and Drug Disposition 30(8):437-447, 2009.
  50. Ogungbenro, K., A. Dokoumetzidis, and L. Aarons. Application of optimal design methodologies in clinical pharmacology experiments. Pharmaceutical Statistics 8(3):239-252, 2009.
  51. Okusanya, O.O., S.M. Bhavnani, J. Hammel, P. Minic, L.J. Dupont, A. Forrest, G.-J. Mulder, C. Mackinson, P.G. Ambros, and R. Gupta. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrobial Agents and Chemotherapy 53(9):3847-3854, 2009.
  52. Otero, J. L., N. Mestorino, and J. O. Errecalde. Pharmacokinetics of enrofloxacin after single intravenous administration in sheep. Revue Scientifique Et Technique-Office International Des Epizooties 28(3):1129-1142, 2009.
  53. Panetta, J.C., A. Gajjar, N. Hijiya, L.J. Hak, C. Cheng, W. Liu, C.H Pui, and M.V. Relling. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clinical Pharmacology and Therapeutics 86(6):651–658, 2009.
  54. Park, D.M., D.D. Shah, M.J. Egorin, and J.H Beumer. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. Journal of Neuro-Oncology 93(2):279-283, 2009.
  55. Pavlovsky, C., M.J. Egorin, D.D. Shah, J.H. Beumer, S. Rogel, and S. Pavlovsky. Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 29(9):1152-1156, 2009.
  56. Rodvold, K.A., D.P. Nicolau, T.P. Lodise, M. Khashab, G.J. Noel, J.B. Kahn, M. Gotfried, S.A. Murray, S. Nicholson, S. Laohavaleeson, P.R. Tessier, and G.L. Drusano. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole. Antimicrobial Agents and Chemotherapy 53(8):3294-3301, 2009.
  57. Rubino, C., S. Bhavnani, P. Ambrose, A. Forres, and J. Loutit. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulmonary Pharmacology and Therapeutics 22(4):269-285, 2009.
  58. Rubino, C.M., S.A. Van Wart, S.M. Bhavnani, P.G. Ambrose, J.S. McCollam, and A. Forrest. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrobial Agents and Chemotherapy 53(10):4422-4428, 2009.
  59. Scaglione, F., S. Esposito, S. Leone, V. Lucini, M. Pannacci, L. Ma, and G.L. Drusano. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. European Respiratory Journal 34(2):392-400, 2009.
  60. Sermsappasuk, P. and M. Weiss. Modeling of α1-adrenoceptor-mediated temporal dynamics of inotropic response in rat heart to assess ligand binding and signal transduction parameters. British Journal of Pharmacology 156(6):764-773, 2009.
  61. Shah, D.K., B.S. Shin, J. Veith, K. Toth, R.J. Bernacki, and J.P. Balthasar. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. The Journal of Pharmacology and Experimental Therapeutics 329(2):580-591, 2009.
  62. Shen, J., A.M. Carcaboso, K.E. Hubbard, M. Tagen, H.G. Wynn, J.C. Panetta, C.M. Waters, M.A. Elmeliegy, and C.F. Stewart. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid. Cancer Research 69(14):5885- 5892, 2009.
  63. Shi, S. and A.J. Hickey. Multivariate data analysis as a semi-quantitative tool for interpretive evaluation of comparability or equivalence of aerodynamic particle size distribution profiles. American Association of Pharmaceutical Scientists 10(4):1113-1120, 2009.
  64. Shin, B.S., S.H. Hong, J.B. Bulitta, J.B. Lee, S.W. Hwang, H.J. Kim, S.D. Yang, H.S. Yoon, D.J. Kim, B.M. Lee, and S.D. Yoo. Physiologically based pharmacokinetics of zearalenone. Journal of Toxicology and Environmental Health, Part A. 72(21 & 22):1395-1405, 2009.
  65. Siluk, D., D.E. Mager , H.S. Kim , Y. Wang , A.M. Furimsky , A. Ta , L.V. Iyer , C.E. Green, and I.W. Wainer . Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat. Xenobiotica 40(3):195-206, 2009.
  66. Singh, R., K.R. Ledesma, K. Chang, J. Hou, R.A. Prince, and V.H. Tam. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. Journal of Antimicrobial Chemotherapy 64(3):556-562, 2009.
  67. Sleasman, J.W., B.L. Robbins, S.J. Cross, J.C. Lindsey, J.M. Kraimer, B.E. Heckman, H.L. Sprenger, N.B. Tustin, C.H. Rose, P.A. Poston, E.F. Neal, G.E. Pakes, M. Nikanjam, and E.V. Capparelli. Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults. Clinical pharmacology Therapeutics 85(4):394-401, 2009.
  68. Tang, L., R. Singh, Z. Liu, and M. Hu. Structure and concentration changes affect characterization of UGT isoform-specific metabolism of isoflavones. Molecular Pharmaceutics 6(5):1466-1482, 2009.
  69. Touw, D.J., E.M. Westerman, and A.J. Sprij. Therapeutic Drug Monitoring of Aminoglycosides in Neonates. Clinical Pharmacokinetics 48(2):71-88, 2009.
  70. Treviño, L.R., N. Shimasaki, W. Yang, J.C. Panetta, C. Cheng, D. Pei, D. Chan, A. Sparreboom, K.M. Giacomini, C.-H. Pui, W.E. Evans, and M.V. Relling. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. Journal of Clinical Oncology 27(35):5972-5978, 2009.
  71. Van den Anker, J.N., P. Pokorna, M. Kinzig-Schippers, J. Martinkova, R. de Groot, G.L. Drusano, and F. Sorgel. Meropenem pharmacokinetics in the newborn. Antimicrobial Agents and Chemotherapy 53(9):3871-3879, 2009.
  72. Wagner, L.M., J.G. Villablanca, C.F. Stewart, K.R. Crews, S. Groshen, C.P. Reynolds, J.R. Park, J.M. Maris, R.A. Hawkins, H.E. Daldrup-Link, H.A. Jackson, and K.K. Matthay. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Journal of Clinical Oncology 27(8):1290-1296, 2009.
  73. Warn, P.A., A. Sharp, A. Parmar, J. Majithiya, D.W. Denning, and W.W. Hope. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, the importance of tissue concentrations and the impact of immune status on the antifungal effect. Antimicrobial Agents and Chemotherapy 53(8):3453-3461, 2009.
  74. Weiss, M., R. Hassna, P. Sermsappasuk, and T. Bednare. Pharmacokinetic-pharmacodynamic modeling of the effect of propofol on [alpha]1-adrenoceptor-mediated positive inotropy in rat heart. European Journal of Pharmaceutical Sciences 38(4):389-394, 2009.
  75. Woo, S., D. Pawaskar, and W.J. Jusko. Methods of utilizing baseline values for indirect response models. Journal of Pharmacokinetics and Pharmacodynamics 36(5):381-405, 2009.
  76. Xu, H.Y., K.H. Kulkarni, R. Singh, Z. Yang, S.W.J. Wang, V.H. Tam, and M. Hu. Disposition of naringenin via glucuronidation pathway is affected by compensating efflux transporters of hydrophilic glucuronides. Molecular Pharmaceutics 6(6):1703-1715, 2009.
  77. Yates, J.W.T. An implementation of the expectation-maximisation (EM) algorithm for population pharmacokinetic-pharmacodynamic modelling in ACSLXTREME. Computer Methods and Programs in Biomedicine 96(1):49-62, 2009.
  78. Younis, I.R., S. Malone, H.S. Friedman, L.J. Schaaf, and W.P. Petros. Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. Cancer Chemotherapy and Pharmacology 63(3):517-524, 2009.
  79. Zamboni, W.C, S. Strychor, L. Maruca, S. Ramalingam, B.A. Zamboni, H. Wu, D.M. Friedland, R.P. Edwards, R.G. Stoller, C.P. Belani, and R.K. Ramanathan. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies. Clinical Pharmacology and Therapeutics 86(5):519-526, 2009.